Latest Breaking News On - Prnewswire redhill biopharma ltd - Page 13 : comparemela.com

TEL AVIV, Israel and RALEIGH, N.C., May 27, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the first quarter ended March 31, 2021. Dror Ben-Asher, RedHill s Chief Executive Officer, said: The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19 therapeutics development. Opaganib, one of the most advanced and promising novel, dual-mode of action, oral drug candidates in development for COVID-19, now has almost 100% enrollment in its global 464-patient Phase 2/3 study in severe COVID-19. Mr. Ben-Asher continued: Commercially, a strong end to the first quarter has set up 2021 for growth, reversing a slow start to the year across the industry. Movantik s new prescriptions in the first quarter outperformed the same quarter last year, while Talicia s growth in prescription volume, repeat pres

United statesUnited kingdomAmber fennellDror ben asherBryan gibbsRedhill biopharmaAstra zenecaAdi frishMicha ben chorinNational cancer instituteRedhill biopharma incAstrazeneca pharmaceuticalsRedhill biopharma ltdDevelopment expensesCompany annual report on formCompany expanded access program